Europe’s Leading Pharma Supply Chain Event
Transforming Pharma Supply Chain. Together
Europe’s leading event for pharma supply chain leaders and their teams
LogiPharma is the largest global end-to-end supply chain event for pharma supply chain leaders, their teams and service partners, uniquely bringing together supply chain leaders with their logistics, transportation and distribution, planning teams, IT, quality, sourcing and procurement.
Industry Leading Experts Speaking at LogiPharma Include:
Vice President, EMEA Supply Operations & Customer Support
Transportation Planning and Logistics Strategy Director
Bristol Myers Squibb
Director,Head of IL/APAC region, Warehousing & Distribution Network
VP Supply Chain, P&M
Sun Pharmaceutical Industries
Head of SCM & Distribution
Corporate Vice President Supply Chain Management
Alessandro de Luca
SVP Head of Global Supply Network Operations
Head of Partner Management
F. Hoffmann-La Roche
LogiPharma is Europe’s only pharma supply chain event with representation from every one of the top 15 global pharma companies. Ensure you deliver your supply chain value proposition through idea sharing and networking with more than 60 top-level pharma speakers and 500+ highly-engaged attendees across 75 bespoke presentations and small-group formats. Through interactive discussion and debate, learn practical solutions to optimise your supply chain value, visibility, flexibility and customer service - whilst saving costs, reducing risk, and remaining compliant.
Why attend LogiPharma 2016?
- Your opportunity to meet, interact and benchmark with senior supply chain professionals from leading pharma companies to make essential contacts and help shape your supply chain strategy of the future
- Provides access to innovative solutions on how you can achieve end-to-end visibility and flexibility to meet the product lifecycle management needs of your changing product portfolio
Learn practical case examples from pharma, regulators and key service providers on how to remain globally compliant (including global serialisation requirements, GDP guidelines and the Falsified Medicines Directive)